• ADCT-402 is a novel CD19-targeted ADC delivering SG3199, a highly cytotoxic DNA minor groove interstrand cross-linking PBD dimer warhead
3
damage. Pharmacokinetic analysis in rat and cynomolgus monkey showed excellent stability and tolerability of Together, these impressive data were used to support the clinical testing of this novel ADC in patients with CD19-expressing B-cell malignancies.
For personal use only. on January 16, 2018. by guest www.bloodjournal.org From CD19 has rapid internalization kinetics 8, 9 and it is not shed into the circulation 10 . These features, coupled with its differential and favourable expression profile, make CD19 an ideal target for the development of antibody-drug conjugates (ADCs) to treat B-cell malignancies.
Indeed, anti-CD19 auristatin containing ADC denintuzumab mafodotin (SGN-CD19A) 11 and maytansinoid-containing coltuximab ravtansine (SAR3419) 12 have been investigated in the clinic.
As an alternative to the delivery of tubulin binding-based warheads, novel ADCs delivering highly cytotoxic pyrrolobenzodiazepine (PBD) dimers have been developed [13] [14] [15] . PBD dimers are a class of exquisitely potent DNA minor groove interstrand cross-linking agents 16 ; one of which, SG2000 (SJG-136) has shown activity against both solid tumor and haematological malignancies 17, 18 . Advantages over ADCs employing other warheads including tubulin inhibitors (e.g. auristatins and maytansinoids), DNA cleavage agents (e.g. calicheamicin)
and classical chemotherapeutics, include the ability to target low copy number antigens and tumor-initiating cells 14 , and to exploit low drug-antibody ratios (DARs). Because of their novel
For personal use only. on January 16, 2018. by guest www.bloodjournal.org From mechanism of action, PBD-containing ADCs are active in tumors inherently resistant to other warhead types and against multidrug-resistant cancers 13 .
PBD dimer SG3199 19 is the released warhead component of the ADC payload tesirine (SG3249) 20 , currently being evaluated clinically in several ADCs including ADCT-301, ADCT-502, MEDI3726 and rovalpituzumab tesirine (Rova-T) for which Phase I data in small cell lung cancer has been reported 21 , and which is currently in several Phase II and Phase III studies.
Here, we report the preclinical evaluation of the novel anti-CD19 ADC (loncastuximab tesirine) containing the PBD dimer payload tesirine. On the basis of these impressive pre-clinical data, this agent is currently being evaluated in Phase I studies of both R/R NHL and R/R B-ALL.
METHODS

Synthesis of ADCs
RB4v1.2 antibody was conjugated to tesirine essentially as previously described 15 . The ADCs RB4v1.2-DM4 and hBU12-mc-MMAF were generated by Concortis (San Diego, USA)
as described in 22 and in patent US 8,242,252 B2, respectively.
Characterisation of ADCT-402 by SEC, HIC and RPLC
Characterisation of synthesised ADCT-402 was performed by size exclusion chromatography (SEC), hydrophobic interaction chromatography (HIC) and reduced reverse phase liquid chromatography (RPLC), as previously described 15 .
Human cell lines
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The source of cell lines used in this study along with cell growth media are shown in Supplementary Table S1 .
CD19 cell surface density
Cell surface CD19 density was determined using Bangs Laboratory Quantum Simply Cellular Anti-human IgG beads according to the manufacturer's instructions.
In vitro cell killing and bystander assay
Cell lines were incubated in growth medium with serial dilutions of ADCT-402, the isotype control ADC, or the free warhead SG3199 for 5 days at 37 °C in a 5% CO 2 -gassed, 
Internalization studies
Cells were exposed to ADCT-402 for 1 h at 4˚C and then incubated at 37˚C where appropriate. Following permeabilization of cells using Tween-20 (0.1% v/v in PBS) for 15 min, samples were washed with PBS and centrifuged at 4000 rpm (4˚C). Removal of the supernatant was followed by addition of rabbit mAb LAMP-1 (1:400; Cell Signalling) for 1 h on ice. A further wash step was followed by adding both Alexa Fluor 488 goat anti human 
In vitro and in vivo cross-linking determination
Quantification of in vitro and in vivo cross-links was done by the single cell gel electrophoresis (comet) assay 23 following the protocol and reagents previously described 15 .
Assessment of ADCT-402 efficacy in in vivo models
All animal studies were performed in facilities that are accredited by the Association for not reach the endpoint were euthanized at the end of the study, and assigned a TTE value equal to the last study day. The logrank test was employed to determine the significance of the difference between the overall survival experiences (survival curves) of two groups, based on their TTE values.
Immunohistochemistry of tumor xenografts and clinical samples sections
Detection of phospho-histone H2A.X (Cell signalling #2577) and anti-PBD (Mouse monoclonal 14B3-B7; Spirogen) in murine FFPE tissue sections was performed using the Leica Bond Max automated staining platform. In brief, both primary antibodies were applied at 1:50 dilution for 30 min, following antigen retrieval of sections using Epitope retrieval solution 2 (Leica Biosystems). Peroxidase block (3-4% (v/v) H 2 O 2 ) followed primary antibody application and antibody detection was performed using the Bond Polymer refine detection system (Leica Biosystems; DS9800). Detection of human CD19 (Leica NCL-CD19-163) in FFPE tissue sections of murine xenograft and human clinical samples was performed using the Roche BenchMark Ultra staining system. In brief, CD19 primary antibody was applied for 30 min at 1:50 dilution following antigen retrieval of sections using CC1 solution (Ventana) for 60 min and a peroxidase blocking step. Detection of anti-CD19 antibody was performed using the Optiview DAB detection kit (# 760-700).
Human lymphoma and leukaemia cases enrolled in this study (Table 1) 
Assessment of ADCT-402 pharmacokinetics (PK)
All animal studies were performed at research facilities AAALAC accredited.
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Blood was collected from tail veins at specified time points; serum was isolated and stored at -80°C.
Male and female purpose bred Cynomolgus monkeys (Macaca fascicularis) were dosed IV with ADCT-402. Blood was collected from vena cephalica antebrachii or vena saphena at specific time points; serum was isolated and stored at -80°C.
In rat and monkey serum, quantification of total antibody and ADC (DAR≥ 1) were determined using optimized ECLIA homogenous formats. Calibration curves, QCs and study samples were diluted and mixed with a biotinylated anti-idiotypic antibody for both the total antibody and ADC measurements (biotinylated anti-PBD antibody for ADC in the monkey) and a Sulfo-tag labelled anti-idiotypic antibody for total antibody and a Sulfo-tag labelled anti-PBD antibody for the ADC (Sulfo-tag labelled anti-idiotypic antibody for ADC in the monkey) to allow complex formation. The complex was added to streptavidin coated MSD plates and, following the addition of read buffer, the plate was read on the MSD QuickPlex Plate Reader (6000 Sector Imager (MSD) for the monkey).
The determination of free SG3199 in cynomolgus monkey serum was performed by LC-MS/MS and used deuterium-labelled SG3199 (SG3199-d10) as internal standard. Isolation of SG3199 (and spiked SG3199-d10) was performed by reduction with cyanoborohydride overnight and followed by off-line solid phase extraction using Oasis HLB 96-well µElution Plate, 30 µm Particle Size. The purified samples were analyzed using an AB Sciex Qtrap 5500 LC-MS/MS system with a Zorbax SB-AQ Rapid Resolution HT (2.1 x 50 mm; 1.8 µm)
column.
The PK analysis was performed using Phoenix WinNonlin Version 6.2 with noncompartmental analysis. Figure 3B .
Cross-links form after an initial delay, reaching a peak at around 12 h, which persist up to 36
h. In contrast, the free warhead SG3199 reached the peak of cross-linking during the initial In the same Ramos model, ADCT-402 was tested together with the CD19-targeted ADCs delivering maytansinoid (RB4v1.2-DM4, DAR=3.3) or auristatin (hBU12-mc-MMAF, DAR=4.2) warheads. ADCT-402 at a single dose of 1 mg/kg was remarkably superior to both the ADCs delivering tubulin binders at an equivalent single dose ( Figure 4B ). This superiority was maintained for ADCT-402 at 1 mg/kg even when the comparator ADCs were administered at higher doses with multiple administrations; 3.3 mg/kg, q4dx2 for RB4v1.2-DM4 and 3 mg/kg, q4dx4 for hBU12-mc-MMAF, respectively ( Figure 4B ). The equivalent warhead amounts administered are given in Table S2 and Kaplan-Meier survival curves are shown in Figure S1B . ADCT-402 administered at 1 mg/kg induced a significant increase in survival compared to both comparator ADCs irrespective of dose level and frequency of administration (log-rank test, p≤0.001 for each comparison).
In this same model, while a single dose of ADCT-402 at 1 mg/kg gave 10/10 TFS ( Figure   4C ), fractionating the dose to 0.33 mg/kg given weekly x 3, or every 4 days x 3, did not achieve the same level of efficacy ( Figure 4C ).
In a disseminated Ramos model, single dose ADCT-402 also showed significant extension of survival in comparison to controls (log-rank test, p≤0.001, Figure 4D ) with 9/10 and 10/10 animals surviving at day 91 for the 0.33 and 1 mg/kg groups, respectively, compared to no survival at day 19 for the vehicle and 1 mg/kg non-target ADC groups.
ADCT-402 also showed dose-dependent activity in the CD19-expressing Daudi xenograft model ( Figure 5A ). At a single dose of 0.3 mg/kg all the animals achieved complete regression with 7/10 classified as TFS at the end of the study (day 73). Kaplan-Meier survival curves show the dose-dependent extension of survival (log-rank test, p≤0.001 for each comparison, Figure S2A ).
ADCT-402 was less effective at treating the WSU-DLCL2 xenograft model ( Figure 5B ).
Although a clear dose-response was observed, the highest single dose used (1 mg/kg) only For personal use only. on January 16, 2018. by guest www.bloodjournal.org From produced a 30 day tumor growth delay. Yet, ADCT-402 resulted in significant, dosedependent extension of survival (log-rank test, p≤0.002 for each comparison, Figure S2B ).
In a second disseminated model (NALM-6), ADCT-402 at 0.33 and 1 mg/kg single dose produced a significant increase in survival compared to control ADC (log-rank test, p≤0.001, Figure 5C ). At a dose of 1 mg/kg, 10/10 animals survived 90 days compared to only 21 days for the vehicle treated group.
ADCT-402 Pharmacodynamics
In mice with Ramos s.c. tumors, a single dose of ADCT-402 was administered at 0.3 or 1 mg/kg ( Figure S3 ). Twenty-four h after treatment, excised tumors showed a dose-related increase in staining intensity by an anti-PBD drug-linker antibody and a γ-H2AX antibody ( Figure 6A ). In contrast, tumors excised from mice treated with a non-targeted ADC, containing the same PBD dimer warhead, at 1 mg/kg did not show increased staining compared to vehicle control animals. CD19 staining remained high and homogeneous in all treatment groups ( Figure 6A ).
Tumor samples were analysed for formation of DNA interstrand cross-linking and γ-H2AX foci. A significant increase in the level of γ-H2AX foci was observed in tumor cells at both ADCT-402 dose levels ( Figure 6B ), with no significant increase seen with the non-targeted ADC. DNA interstrand cross-linking in tumor cells, measured as the reduction in OTM, was also significant at both dose levels of ADCT-402 compared to vehicle or non-targeted ADC ( Figure 6C ). In contrast, no cross-linking was observed in PBMCs samples taken from the same mice ( Figure S4 ). The selective targeting of ADCT-402 to human CD19-expressing tumor cells, resulting in the formation of DNA interstrand cross-links and an associated DNA damage response are therefore confirmed in vivo.
ADCT-402 Pharmacokinetics in Rat and Cynomolgus Monkey
For personal use only. on January 16, 2018. by guest www.bloodjournal.org From Quantitation of total or PBD-conjugated antibody was determined in rat serum following a single administration of 1.5 mg/kg to non-tumor bearing rats ( Figure 7A ). The half-life for total and PBD-conjugated antibody were 9.9 and 10.4 days, respectively (ADCT-402 does not cross-react with rat CD19) (Table S3) , indicating typical IgG1 kinetics and excellent stability in vivo.
Quantitation of total antibody, PBD-conjugated antibody and free SG3199 was also determined following administration of 0.6 mg/kg ADCT-402 on days 1 and 22 to cynomolgus monkeys ( Figure 7B ). The exposure profile of ADCT-402 indicates typical IgG1 kinetics, a 14 day half-life (ADCT-402 does not cross-react with cynomolgus monkey CD19) (Table S3) , and excellent stability in vivo.
ADCT-402 was well tolerated in the rat and monkey studies with an acceptable safety profile. A CD19-directed ADC employing a first-generation PBD dimer with linker site attachment at the C2 position has recently been described 27 .
ADCT-402 cytotoxicity showed a weak, yet significant negative linear correlation with cell surface CD19 target expression in a panel of ten hematological cancer cell lines (eight CD19-positive and two CD19-negative). This is in contrast to previously reported data for ADCT-301 and SGN-CD19B, which failed to show a clear relationship between sensitivity and antigen expression level 15, 27 . In the case of ADCT-301, the limited number of CD25-positive cell lines available all had high CD25 expression which may have been above a threshold for accurately determining cytotoxic sensitivity. In this study, all cell lines, including those negative for CD19 expression, were sensitive to the free warhead SG3199, consistent with the non-targeted delivery of the warhead alone. Some differential sensitivity, unrelated to CD19 expression, was observed for SG3199. Notably, the mantle cell lymphoma cell line Granta-519 and acute lymphoblastic leukemia cell line Nalm-6 were the most sensitive to 
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